Silvia C.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase Ib/II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Atezolizumab in Patients with Advanced Solid Tumors
- Phase II Study of Rilvegostomig and Ramucirumab in Combination Therapy for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase 2 Evaluation of Cemiplimab and BNT116 Combination Versus Cemiplimab Monotherapy in Advanced NSCLC with PD-L1 Expression ≥50%
Data & Insights
Has run more than one trial at 77 of 232 partner sites.
Specializations
Lung Cancer Research
This investigator specializes in treating non-small cell lung cancer (NSCLC) across various stages and presentations, including advanced metastatic disease and Pancoast tumors. Their research encompasses innovative therapeutic approaches combining immunotherapy and chemotherapy for both operable and advanced cases.
- Advanced NSCLC Treatment Protocols
- Resectable Lung Cancer Management
- Cancer Vaccine Development
Ovarian Cancer Studies
The investigator conducts research in advanced epithelial ovarian cancer, with particular focus on high-grade ovarian cancer and related conditions including fallopian tube cancer and primary peritoneal cancer. Their work involves evaluating maintenance therapies and combination treatment approaches.
- Advanced Stage Treatment Strategies
- Post-surgical Therapeutic Protocols
- Targeted Maintenance Therapy
Solid Tumor Therapeutics
Research extends to locally advanced and metastatic solid tumors, investigating novel therapeutic combinations. The investigator explores antibody-drug conjugates and their combination with immunotherapy agents for various tumor types.
- Combined Modality Treatments
- Novel Drug Development
- Advanced Disease Management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.